Literature DB >> 26787500

Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?

Annelies Demeyer1, Jens Staal1, Rudi Beyaert2.   

Abstract

MALT1 is a signaling protein that plays a key role in immunity, inflammation, and lymphoid malignancies. For a long time MALT1 was believed to function as a scaffold protein, providing an assembly platform for other signaling proteins. This view changed dramatically when MALT1 was also found to have proteolytic activity and a capacity to fine-tune immune responses. Preclinical studies have fostered the belief that MALT1 is a promising therapeutic target in autoimmunity and B cell lymphomas. However, recent studies have shown that mice expressing catalytically-inactive MALT1 develop multi-organ inflammation and autoimmunity, and thus have tempered this initial enthusiasm. We discuss recent findings, highlighting the urgent need for a better mechanistic and functional understanding of MALT1 in host defense and disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MALT1; inflammation; lymphocytes; lymphoma; protease; therapeutic targeting

Mesh:

Substances:

Year:  2016        PMID: 26787500     DOI: 10.1016/j.molmed.2015.12.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  28 in total

1.  The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes.

Authors:  Inna S Afonina; Elien Van Nuffel; Griet Baudelet; Yasmine Driege; Marja Kreike; Jens Staal; Rudi Beyaert
Journal:  EMBO Rep       Date:  2016-04-25       Impact factor: 8.807

Review 2.  Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome.

Authors:  Inna S Afonina; Zhenyu Zhong; Michael Karin; Rudi Beyaert
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

3.  Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.

Authors:  S Van Gucht; R Beyaert; E Kip; J Staal; H G Tima; L Verstrepen; M Romano; K Lemeire; V Suin; A Hamouda; M Baens; C Libert; M Kalai
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

4.  Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Authors:  Pieter Van Vlierberghe; Steven Goossens; Tim Pieters; Sara T'Sas; Stijn Vanhee; André Almeida; Yasmine Driege; Juliette Roels; Wouter Van Loocke; Willem Daneels; Mathijs Baens; Arnaud Marchand; Maaike Van Trimpont; Filip Matthijssens; Julie Morscio; Kelly Lemeire; Béatrice Lintermans; Lindy Reunes; Patrick Chaltin; Fritz Offner; Jo Van Dorpe; Tino Hochepied; Geert Berx; Rudi Beyaert; Jens Staal
Journal:  J Exp Med       Date:  2021-08-18       Impact factor: 14.307

5.  MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.

Authors:  Jia-Ying Lloyd Lee; Prasanna Ekambaram; Neil M Carleton; Dong Hu; Linda R Klei; Zongyou Cai; Max I Myers; Nathaniel E Hubel; Lidija Covic; Sameer Agnihotri; Daniel Krappmann; Frédéric Bornancin; Adrian V Lee; Steffi Oesterreich; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

Review 6.  Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease.

Authors:  S-K Friedrich; P A Lang; J Friebus-Kardash; V Duhan; J Bezgovsek; K S Lang
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

7.  MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice.

Authors:  Inna S Afonina; Rudi Beyaert; Elien Van Nuffel; Jens Staal; Griet Baudelet; Mira Haegman; Yasmine Driege; Tino Hochepied
Journal:  EMBO Rep       Date:  2020-04-28       Impact factor: 8.807

8.  Porcine Reproductive and Respiratory Syndrome Virus Adapts Antiviral Innate Immunity via Manipulating MALT1.

Authors:  Han Gu; Suya Zheng; Guangwei Han; Haotian Yang; Zhuofan Deng; Zehui Liu; Fang He
Journal:  mBio       Date:  2022-04-25       Impact factor: 7.786

9.  Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients.

Authors:  Chun-Nan Yeh; Yu-Chan Chang; Yeu Su; Dennis Shin-Shian Hsu; Chi-Tung Cheng; Ren-Chin Wu; Yi-Hsiu Chung; Kun-Chun Chiang; Ta-Sen Yeh; Meng-Lun Lu; Chun-Yu Liu; Peter Mu-Hsin Chang; Ming-Han Chen; Chi-Ying F Huang; Michael Hsiao; Ming-Huang Chen
Journal:  Oncotarget       Date:  2017-12-08

Review 10.  NF-κB in Hematological Malignancies.

Authors:  Véronique Imbert; Jean-François Peyron
Journal:  Biomedicines       Date:  2017-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.